| 1 |
Development of antibodies to induce lung regeneration for the treatment of emphysema |
| Small Molecules |
Pulmonary emphysema |
Robo1 |
Hit |
Asan Medical Center |
HN21C0202 |
|
| 2 |
Development of therapeutic fully human monoclonal antibody FBPF-11X as lead compound for pulmonary fibrosis |
| Antibody |
Pulmonary fibrosis |
FBFP-101-T |
Lead |
FNCT Biotech |
HN22C0683 |
|
| 3 |
Derivation of lead candidates for idiopathic
pulmonary fibrosis treatment through inhalant
optimization of integrin selective binding peptide |
| Peptide |
IPF |
Integrin αVβ-3,5,6 |
Lead |
NEXEL |
HN22C0012 |
|
| 4 |
Development of drug candidate against respiratory infection using Foxj1 as a target |
| Small Molecules |
Pneumonia |
Foxj1 |
Lead |
Chonnam National University |
HN21C0513 |
|
| 5 |
Elicitation of lead compounds for the treatment of chronic obstructive pulmonary disease targeting leucotriene B4 receptor BLT2 |
| Small Molecules |
COPD |
BLT2 |
Lead |
Korea university |
HN21C0996 |
|
| 6 |
Study on lead generation for IPF (idiopathic pulmonary fibrosis) drug based on AI platform |
| Small Molecules |
IPF |
CHIT1 |
Lead |
INNOVO Therapeutics |
HN21C0205 |
|
| 7 |
Discovery of a ‘First.In.Class’ New Drug for IPF Treatment |
| Small Molecules |
Idiopathic pulmonary fibrosis |
ARPC2 |
Candidate |
SapiensBio.Inc |
RS-2023-00283815 |
|
| 8 |
ATB-610: Small molecule developing as a inhaler with reducing toxicity by inhibiting ALK5 selectively for IPF treatment |
| Small Molecules |
IPF |
ALK5 |
Candidate |
Autotelic Bio |
RS-2022-00165740 |
|
